Oral pill trial to halt HIV in women is stopped
Thursday 21 April 2011
A trial of an oral pill aimed at preventing HIV infection in African women has been halted due to poor results, the trial operator Family Health International announced this week.
The US Centers for Disease Control described the results as "disappointing," and in a Monday statement said the trial's monitoring committee had decided it "could not demonstrate efficacy even if it continued to its originally planned conclusion."
The same oral treatment, known as pre-exposure prophylaxis (PrEP) for HIV prevention, has been shown to reduce risk of HIV transmission among men who have sex with men by between 73 and 90 percent.
The trial included 2,000 African women in Kenya, South Africa and Tanzania. Trial subjects were taking oral tenofovir and emtricitabine, marketed as Truvada by the California-based Gilead Sciences Inc., or a placebo.
Researchers said that the rate of new HIV infections in both the drug and placebo groups was the same, with 56 new HIV cases equally distributed across both sections of the study.
They also noted that the overall pregnancy rate among women in the study was nine percent, with the highest rates seen in women taking birth control pills. More study is needed to determine if the anti-HIV treatment had a disabling effect on the oral contraceptives.
"While this development was not what we would have hoped for, Gilead believes that antiretroviral therapies remain a promising potential HIV prevention strategy," Gilead Sciences said in a statement.
"We continue to support ongoing studies evaluating the company's antiretroviral therapies as potential preventatives."
The CDC sent out an email announcement about the FHI trial's end on Monday.
"Given today's results, CDC cautions against women using PrEP for HIV prevention at this time," it said.
"We will not know if PrEP is effective for women, couples, or injection drug users until the conclusive results of this and other trials are reported."
Harry Potter actor suffered 'severe flu-like symptoms' on a flight from London to Orlando
First full-length look is finally here
World cities ranked in terms of safety, food security and 'liveability'
Life & Style blogs
Snapchat removed the Best Friends list feature and 'stalkers' are upset
Baldness could soon be treated using stem cells, scientists hope
A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
Eight-year-old girl Camilla Lisant suggests possible cancer treatment to her scientist father over the dinner table
Lack of medically trained staff leaves NHS 111 phone service struggling to cope, insider claims
- 2 The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
- 3 Ball pool for adults opens in London
- 4 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
- 5 Baldness could soon be treated using stem cells, scientists hope
£26000 - £31000 per annum: Recruitment Genius: A Digital Content Manager is re...
£40000 - £60000 per annum: Recruitment Genius: This is a fantastic opportunity...
£14000 - £17500 per annum: Recruitment Genius: The successful applicant will b...
£41500 per annum: Recruitment Genius: This company is going through a period o...